Astellas is focusing on solid tumors and regeneration of the back of the eye. For gene therapy, the Japanese pharma remains hopeful that it can eventually build a presence in neuromuscular ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and safety of PADCEV, or enfortumab vedotin-ejfv, a Nectin-4 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Astellas confirmed today that it will withdraw ... That approval set up a market clash with Apellis Pharma's complement C3 inhibitor Syfovre (pegcetacoplan), which was cleared a few months earlier.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

CHGCY Chugai Pharmaceutical Co., Ltd.

A dealership's rating is based on all of their reviews, with more weight given to recent reviews. Includes reviews of Autohaus on Edens from DealerRater. Want to share your experience with this ...

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...